First-in-Human Study of HH160 for Advanced Solid Tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and able to give informed consent
- You have advanced solid tumor cancer confirmed by biopsy or tissue sample
- You have at least one tumor lesion that can be measured on imaging scans
- You are well enough to do light activities (ECOG score 0–1) with life expectancy of at least 12 weeks
- Your organ function (kidney, liver, heart, blood counts) meets specific safety thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.